Himalaya's Logo
  Search
  Health Help
 
 
   
Press Room
Himalaya in the News
Press Releases
News Archives
Media Contact
   
 
Direct from Himalaya online.
 
 
Click to select your location.
 
   
Bangalore, August 23, 2002  
Himalaya launches 2 drugs for women  

AYURVEDIC major Himalaya Drug Company has added two key women's healthcare products to its portfolio.

Reosto is aimed at osteoporsis and Menosan for menopausal problems, taking the Rs.250 crore company's pharma portfolio up to 35.

The products are currently being promoted through the 'ethical' route in phases.

The next launch will be a paediatric brand, which should be out around the year-end, Mr. Philipe J.Haydon, General Manager - Pharma Marketing, told Business Line.

While the twin launches are expected to net a turnover of Rs. 7 crore this year in their market segment, they could well turn out to be another Liv.52 - the Himalaya flagship - in the longer run, he said.

For, the market for these particular women's healthcare products is now wide open; the anti-osteoporsis segement is around Rs 460 crore, inclusive of Rs 205 crore for the main hormone therapy and Rs 262 crore by way of calcium and Vitamin D supplements.

Liv.52, according to the February ORG report, is worth Rs 64 crore and has been rated the number one liver therapy and number three among all domestic pharma products.

Reosto and Menosan are a product of some 10-12 years of research and trials, Mr. Haydon said. Menosan, which is based on phytoestrogens, has no side effects.

Priced at Rs 2 per tablet in a pack of 60, it will be an alternative to HRT (hormone replacement therapy), which has, of late, come in for flak globally for its serious after-effects.

Reosto, which the company calls 'bone insurance', is priced at Rs 1.50 per tablet in a pack of 60 tablets. It is meant to be a low-cost therapy for osteoporosis, which accounts for over 1.5 million fractures a year, mostly among women.

They were promoted first in the overseas market where HRT awareness was far higher than in India.

Branding pays off

SOME seven months since the company adopted its umbrella brand strategy, the positive results are telling, says Mr. Philipe J Haydon, General Manager - Pharma Marketing, Himalaya Drug Company.

Sales in the company's core segment, the Pharma brands, have climbed 45 per cent in the first quarter, while the recently added "Pure Herbs division is doing exceedingly well".

Pure Herbs is now riding on Discovery Channel as part of a co-branding exercise.

In an expanding marketing exercise, 32 more exclusive Himalaya Stores are to be added by the end of this fiscal. Currently, there are 18 franchisee-ownership shops across the country, including three in Bangalore.

All this, according to Mr. Haydon, is in line with Himalaya's vision of touching a turnover of Rs 500 crore by 2005, its diamond year.

 
   
Back

 

 
 
FAQs   |   Glossary   |   Sitemap   |   Privacy Policy   |  Terms of Use  
Copyright © 2002 The Himalaya Drug Company.